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The Southern African HIV Clinicians Society initiated an online
discussion forum on ‘HIV Ethics and Policy’ in 2007. The case
study below concerns the ‘hidden’ costs associated with access
to antiretroviral therapy (ART), and discusses a number of
proposed solutions to the problems faced by indigent patients
with HIV/AIDS (to read the entire debate, see http://groups.
google.com/group/policy-ethics/topics?start=10&sa=N).
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CASE STUDY
Tertiary hospital
At a large tertiary level hospital in South Africa, patients were
in the past expected to contribute to the costs of their care
by paying means-tested fees, per visit to an outpatient clinic,
or per day in case of a hospitalisation. Fees started at R160
per outpatient visit for the lowest income tier. Patients were
exempted from the payment if they could prove that they did
not have a regular income. 
In practice, patients in the lowest income tier were accepted
into the clinic for their first 3 visits, but had to bring proof of
no income at their 4th visit at the latest. During the first year
of the ART clinic’s operation, this proof of income (or the
absence of it) could have been a handwritten affidavit
stamped at their local police station. During the second year,
however, this policy was changed and patients had to supply
a print-out from the employment registry at the Department
of Labour. Hospital staff observed an increase of patients
defaulting from treatment after their third visit. Patients
were complaining that the new procedure meant that they
had to travel to the city centre and queue for a day at the
Department, or sometimes for several consecutive days, in
order to obtain the necessary documentation. In October
2006 hospital fees were abolished for patients accessing the
ART clinic, but patients were still expected to settle their
outstanding fees for the period before this general exemption
took hold. 
An analysis of patients’ transport costs at this clinic shows a
mean cost of almost R26 per visit, with 61% of patients using
minibus taxis as their means of transport. The analysis found
that this amounts to a significant proportion of patients’
income, especially as a monthly expense over a long period of
time. 
Secondary hospital
At another ART clinic in a semi-rural secondary health care
hospital, the same analysis showed that while mean
transport costs are somewhat lower, patients who do not
have the cash for a taxi (about 10% of the clinic population)
walk several hours on foot to get to the clinic. The clinic staff
are concerned that these patients are going to default from
treatment if they get sick or demotivated. 
Primary health care hospital
At a third ART clinic, in a rural primary health care hospital,
patients from the catchment areas of nearby hospitals that
have not yet been accredited for ART are collected by bus
once a week and driven to the ART clinic in a scheme
financed by the provincial Department of Health. The clinic
operates in an area that has no working system of minibus
taxi routes. Patients comment on the significant stigma-
tisation they perceive as being associated with having to wait
for the ‘AIDS buses’ in a central part of their township. 
Questions for discussion
1. Is it ethically sound to exempt the patients at the ART
clinic from the tertiary hospital’s fee policy? 
(a) Should the exemption apply to all ART patients, or
only to those without income or employment? 
(b) In the latter case, how should patients be expected to
prove that they qualify? 
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CASE STUDY RESPONSES
A - SUBMITTED BY JOHN GOSLING
Responses to questions 1 and 2
Patients attending ART clinics should be exempt from all
hospital fees – irrespective of their income. Because of the
extent of the pandemic and the backlog in providing adequate
treatment to the approximate 850 000 people who qualify for
ART, all outpatient and inpatient treatment for HIV/AIDS
should be provided free of cost. This will encourage better
compliance and also pave the way for patients to access
treatment more readily, whether they have financial
constraints or not. 
This tertiary hospital is to be lauded for completely abolishing
hospital fees for those patients attending ART clinics. However,
it would seem unreasonable to expect patients to settle
outstanding fees that were owed before the implementation
of this policy. This is especially churlish in view of the fact that
the Department of Health regularly fails to spend its allocated
budget. Surely some of the unspent finances could be used to
settle this outstanding debt, which is probably not very large
anyway?
The HIV/AIDS pandemic is of such major proportions, and is
claiming the lives of so many whose lives could be extended if
they were able to access ART in a timely fashion (it is currently
estimated that between 800 and 1 000 deaths due to AIDS-
related causes occur every day in South Africa), that there
ought to be no question of having to prove whether or not any
given patient ‘qualifies’ for free treatment.
In Brazil, ART has been free since 1996. The programme
(including aggressive and frank prevention programmes) has
improved the health, and extended the survival, of tens of
thousands of Brazilians.  It has saved the country an estimated
$2.2 billion in hospital costs between 1996 and 2004. Access
to free AIDS treatment has made Brazilians more willing to be
tested for HIV and has made it easier to address the types of
behaviour associated with transmission.1 If the government of
Brazil has been able to provide funding for this treatment
programme, which has been so highly effective, it ought to be
possible for the South African government to do the same. 
The answer to the question whether this policy of free
treatment ought to be applied to all chronic medical
conditions, including inpatient treatment, should be a
resounding yes. Unfortunately, this goal is unrealistic in the
immediate foreseeable future because of a very poorly
administrated Department of Health as well as crumbling
medical infrastructure. However, this goal ought to be one of
the main issues to be revisited by the government and should
be implemented in the very near future.
Response to question 3
The suggestion of travel vouchers is an excellent one. These
ought to be supplied on request to all persons attending ART
clinics. Given that most patients attending public clinics are
indigent, there is little possibility of abuse of such a system.
Travel vouchers would ensure that patients keep their
appointments more regularly and therefore become more
compliant with their ART regimens. Furthermore, it is the
express intent of the state, as enshrined in the Bill of Rights,
that ‘everyone has the right to have access to health care
services’. (section 27(1)(a)). One could argue that this right
would include free transport for those who cannot afford the
taxi fare and who may live at considerable distances from the
clinics.
B – SUBMITTED BY KARIN VAN DEN BERG
It is important to consider that every person in South Africa
who is formally employed pays taxes that are used to fund the
public health care system in this country. The implication is
that those who have the means have already contributed to
the public health care system and therefore should not have
to pay again. Those who are unemployed clearly do not have
the means to contribute, and they should indeed be exempt
from payment. Such a system removes the need for a ‘means
test’ or any expensive debt collection system – a system that
is not working efficiently. The above policy should be
applicable to all persons seeking help at a public health facility,
irrespective of the condition for which the help is sought. 
With regards to the ‘AIDS bus’, it would seem unethical to
provide certain chronically ill people with a ‘better’ or more
comprehensive service than people who have ‘only’ diabetes or
asthma. It implies that one patient is more important than
another. If the same service were provided to all patients
requiring monthly chronic medication, there would be no
stigma associated with using the service. 
CONCLUSION – GESINE MEYER-RATH
1. USER FEES AT HOSPITAL OR CLINIC LEVEL
Background
In 1989 the World Bank, as part of its structural reform
approach, issued a document entitled Financing Health
Services on Developing Countries: An Agenda for Reform.2 It
promoted a number of interventions aimed at improving
2. Should the exemption policy be applied to other patients
in chronic care? 
(a) What about inpatients? 
3. What are possible solutions to the problem of transport
costs? 
(a) Would voucher schemes or the bus scheme
mentioned above be viable alternatives to patient
self-funding of transport? 
(b) What should the criteria be for patients to qualify for
vouchers?
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health sector financing in low-income countries, including the
concept of cost recovery at the level of the health care
provider in form of user fees. Subsequently a number of
countries introduced user fees in both the health and
education systems with varying results, but almost invariably
leading to lower-than-necessary access of health care by the
poorest sectors of society, and to delayed diagnosis and
treatment for a number of diseases, thus ultimately resulting
in higher cost. A case in point is provided by Kenya, where user
fees for public sector outpatient services were introduced in
1989 and withdrawn after only 9 months in 1990.
A study reviewing access to services for sexually transmitted
infections found significant reductions in utilisation during
the period of user fees, with a 60% reduction for men and
35% for women, with one exception. For gonorrhoea, women’s
utilisation increased significantly and progressively during the
user fee period. This, the authors hypothesised, could have
been due to growing rates of infection secondary to falling
rates of treatment.3
The impact of user fees on adherence and mortality in
patients on ART
For ART roll-out programmes, the literature is unequivocal in
describing a detrimental effect of user fees or other cost
contributions by patients on adherence and remaining in care,
and the relative superiority of free provision over provision in
which patients have to bear some or all costs. Table I
summarises the findings of the relevant studies published to
date.
Interestingly, the first two large reviews of the results of ART
programmes in resource-limited settings in terms of mortality
and immunological and virological outcomes over the first 12
months of treatment both compared free-of-charge and fee-
for-service programmes. They found respectively:
■ that ‘provision of treatment free of charge in low-income
settings was associated with lower mortality’,5 and 
■ that ‘the provision of medications free of charge to the
patient was associated with a 29 - 31% higher probability
of having an undetectable viral load at months 6 and 12’.7
A further study looked at the ‘social cost’ of a scheme of user
fees with exemption in treatment centres in Ouagadougou,
Burkina Faso.9 The researchers describe these costs to include,
among others, ’patients’ perception[s] of arbitrariness about
application of exemptions, to difficulties to adjust [the]
payment scheme to changing economic conditions, and to
necessary negotiations within the relationship between
patients and health workers who decide the rate of payment’,
and, at the level of the health care worker, the ‘means and time
necessary for socioeconomic enquiries for exemptions and to
the symbolic cost of choosing between patients’.9
User fees for hospital services in South Africa
In South Africa, user fees are set at the discretion of the
Minister of Health, and in some instances the relevant
provincial member of the Executive Council (MEC) responsible
for health,10 and are mostly applied at tertiary (university
hospital) level. The argument is that these institutions provide
specialised care and have much higher overhead costs than
institutions at secondary and primary levels of care. As
mentioned in the case study, the tertiary hospital in question
has since abolished user fees for patients at the ART clinic. This
correctly led to many Discussion Forum contributors
demanding the same exemption to apply to all patients who
have to access the hospital regularly for chronic care.
Generally, the question remains whether the amount that can
be recouped by charging patients is higher than, and therefore
justifies, the administrative costs of collecting these charges. 
A second argument for introducing user fees, that they help to
minimise the ‘moral hazard’ of unnecessary demand (i.e.
demand for health care that is deemed superfluous or is
demanded at a higher level of care than necessary) does not
hold in the case of ART, and much other chronic care.  This is
because the cost of delaying health care is much higher than
the cost of accessing care as and when the patient deems it
necessary. Comments of contributors to the Discussion Forum
were motivated by concerns about the long-term sequelae of
financially motivated treatment interruption or cessation,
especially the development of drug-resistant virus. Indeed, the
preliminary results of a file review at the tertiary hospital show
that especially during the first months of its operation in
2004, many of the newly joining patients had previously
accessed some form of ART in the private sector, often sub-
optimal dual therapy, and had had to interrupt ‘buying the
drugs’ when they ran out of money. Whether this translates
into higher rates of resistance development for these patients
compared with the clinic population that was treatment-naïve
on entry into to the clinic is still subject to analysis.
2. BUT USER FEES AREN'T THE PROBLEM – WHAT
ABOUT TRANSPORT COST?
Questions 2 and 3 approached the problem of the additional
burden that accessing an ART clinic on a monthly basis poses
to often already overburdened people. The problem of access
costs for chronic health care to the poor has been well
researched, and a large number of remedies have been
designed and tried out in different settings over time. Two of
these remedies were included for discussion, travel vouchers
and designated bus transfers, with the latter potentially re-
introducing the problem of stigma. 
The obstacle of transport cost has been quantified for ART
patients in a few studies. One study involving 789 patients in
public sector and NGO clinics in South Africa showed that
patients paid a median R20, R10 and R27 in accessing a public
urban hospital, a peri-urban and a rural non-governmental
clinic, respectively,11 with the top decile paying R60, R23, and
R71, respectively.  This compares well with the mean cost of
R26 and R19 for patients accessing the urban tertiary care
clinic and the semi-urban secondary care clinic that were
mentioned in the case study. Compared to patients’ income
these costs are high, and it is not clear why they should be
borne by the patient.
Setting 
(number of patients 
Country Years in study) Outcomes Comments
Uganda4 1998 - 2002 St Francis Hospital,  21% of patients Price drops in 2000 led to
Kampala (N = 321) interrupted treatment many patients returning to 
for > 1 year because clinic; regimens often sub-
of financial constraints standard and determined by 
patients’ ability to pay
18 countries in Africa, N/A (before 2006) Review of mortality Provision of treatment 
Asia and South America5 data from treatment free of charge in low-
cohorts in ART-LINC income settings associated 
collaboration, 12 of with lower mortality
which provide ART (adjusted HR 0.23; 
free of charge 95% CI 0.08 - 0.61)
(N = 4810)
India6 N/A (before 2005) Y R Gaitonde Center for Cost was most common ‘Patients seem to be taking 
AIDS Research and Care reason for non-adherence “drug holidays” to
in Chennai (N = 304) (32%) save money’
11 countries in 1997 - 2003 Meta-analysis of Provision of medications
Africa, Asia and effectiveness data free of charge associated
South America7 from clinical trials and with a 29 - 31%
observational studies of higher probability of
ART programmes having an undetectable
(N = 2464) viral load at months 
6 and 12
Uganda8 1997 - 2004 3 treatment centres Monthly income Non-adherence defined as 
in Kampala < 50 US$ was associated > 95% of doses missed 
(N = 304) with non-adherence in last 3 days
(OR = 2.77, 95% 
CI 1.64 - 4.67)
TABLE I. CHARACTERISTICS AND FINDINGS OF STUDIES ON THE IMPACT OF PATIENT CHARGES ON ART OUTCOMES
3. THE WAY FORWARD
There is a great need for policy makers to consult more with
health care practitioners ‘on the ground’ whose work provides
them with unique insights into the obstacles their patients are
struggling with. A number of important initiatives are
currently under way to remedy the situation in South Africa,
ranging from increased lobbying for the economic rights of
people living with HIV/AIDS, to reviewing and improving the
current CD4 count-based disability grant criteria, to
potentially introducing a chronic illness grant. It seems that
after years of political struggle to provide antiretrovirals in the
public sector, and with increasing numbers of patients on
treatment who expand the collective knowledge and
experience of treatment challenges, a second wave of detailed
operational thinking and activism has been initiated. Creative
research is needed to identify feasible and scaleable
interventions that support patients who have expressed their
readiness to take lifelong treatment in putting their conviction
into action. Three years into the public sector roll-out of ART,
the discussion about how to avoid hidden costs and how to
increase support strategies for patients on ART has just begun.
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